Although double-expressor lymphoma (DEL) is considered a group of DLBCL characterized by overexpression of c-MYC (≥40%) and BCL2 (≥50%) by immunohistochemistry, the biopsy in this patient showed co-expression of BCL2 and c-MYC, indicating the aggressive nature of the disease. The gene discussed is MYC; the disease is diffuse large B-cell lymphoma.